A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
A phase 3 trial of Eribulin, Vinorelbine, Gemcitabine and Capecitabine in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
Overview
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01) is a phase 3 interventional study registered as NCT06343948 by Sichuan Baili Pharmaceutical Co., Ltd., with 383 participants enrolled, started 2024-04-24 and due to reach its primary completion in 2026-08. Interventions recorded: BL-B01D1, Eribulin, Vinorelbine, Gemcitabine and Capecitabine.
Similar pages
not linked directly; found by shared links- TrialStudy of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
- TrialAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
- TrialA Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
Shares Eribulin, SystImmune / Sichuan Biokin, Capecitabine, Gemcitabine and the tag pipeline.
- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
Shares SystImmune / Sichuan Biokin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Shares Eribulin, Capecitabine, Gemcitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
- TrialA Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Shares Vinorelbine, Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.